GLMD
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Galmed announced successful first-in-human proof-of-concept results for Colospan's novel intraoperative tissue assessment technologyAug 19, 2026
- Galmed reported initial prostate cancer study results showing Aramchol increased cell death by 3-4 fold compared with enzalutamide alone in prostate cancer modelsAug 18, 2026
- Galmed announced the development of a novel cardiac-targeted LNP formulation for its SCD1 inhibitor AramcholJul 16, 2026
- Galmed Pharmaceuticals restructured acquisition terms for Colospan to prioritize CG-100 commercialization in Europe and shareholder valueJun 22, 2026
- Tissue Dynamics and Galmed partner to develop fibrosis platform for Aramchol-based therapiesMay 7, 2026